WO1999016462A1 - Medicaments utilises pour des maladies occasionnees par une resistance insulinique - Google Patents
Medicaments utilises pour des maladies occasionnees par une resistance insulinique Download PDFInfo
- Publication number
- WO1999016462A1 WO1999016462A1 PCT/JP1998/004293 JP9804293W WO9916462A1 WO 1999016462 A1 WO1999016462 A1 WO 1999016462A1 JP 9804293 W JP9804293 W JP 9804293W WO 9916462 A1 WO9916462 A1 WO 9916462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- irs
- insulin resistance
- protein
- full length
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Definitions
- a source of a substance which is considered to have a binding inhibitory activity may be tested.
- Substance sources include synthetic peptides, small organic compounds, and natural products. Preferably, it has a property that can be used as a pharmaceutical. Specific examples include a combinatorial library of various chemical substances and a synthetic peptide library.
- BSA bovine serum albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/508,691 US6498139B1 (en) | 1997-09-29 | 1998-09-25 | Remedies for diseases caused by insulin resistance |
EP98944230A EP1010433A4 (en) | 1997-09-29 | 1998-09-25 | MEDICINE FOR DISEASES CAUSED BY INSULIN RESISTANCE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26371997 | 1997-09-29 | ||
JP9/263719 | 1997-09-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/508,691 A-371-Of-International US6498139B1 (en) | 1997-09-29 | 1998-09-25 | Remedies for diseases caused by insulin resistance |
US10/085,027 Division US20020132759A1 (en) | 1997-09-29 | 2002-03-01 | Remedies for diseases caused by insulin resistance |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999016462A1 true WO1999016462A1 (fr) | 1999-04-08 |
Family
ID=17393368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/004293 WO1999016462A1 (fr) | 1997-09-29 | 1998-09-25 | Medicaments utilises pour des maladies occasionnees par une resistance insulinique |
Country Status (3)
Country | Link |
---|---|
US (2) | US6498139B1 (ja) |
EP (1) | EP1010433A4 (ja) |
WO (1) | WO1999016462A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2826010B1 (fr) * | 2001-06-14 | 2005-02-25 | Mahmood Salman Al | Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par les cellules endotheliales |
DE10241111A1 (de) * | 2002-09-03 | 2004-03-11 | Ernst-Moritz-Arndt-Universität | Modulation der Insulinsynthese |
US20120041047A1 (en) * | 2010-08-10 | 2012-02-16 | Gene Signal International Sa | Injectable Pharmaceutical Composition for Preventing, Stabilizing and/or Inhibiting Pathological Neovascularization-Related Conditions |
EP2540828A1 (en) | 2011-06-30 | 2013-01-02 | Gene Signal International SA | Composition comprising inhibitors of IRS-1 and of VEGF |
US9682144B2 (en) | 2011-06-30 | 2017-06-20 | Gene Signal International, Sa | Composition comprising inhibitors of IRS-1 and of VEGF |
CN103764830A (zh) | 2011-06-30 | 2014-04-30 | 基因信号国际公司 | 含有irs-1抑制剂和vegf抑制剂的组合物 |
US10052343B1 (en) | 2017-02-03 | 2018-08-21 | Gene Signal International Sa | Sterile formulation comprising a stable phosphorothioate oligonucleotide |
-
1998
- 1998-09-25 US US09/508,691 patent/US6498139B1/en not_active Expired - Fee Related
- 1998-09-25 EP EP98944230A patent/EP1010433A4/en not_active Withdrawn
- 1998-09-25 WO PCT/JP1998/004293 patent/WO1999016462A1/ja not_active Application Discontinuation
-
2002
- 2002-03-01 US US10/085,027 patent/US20020132759A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
CRAPARO A., FREUND R., GUSTAFSON T. A.: "14-3-3 (EPSILON) INTERACTS WITH THE INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND INSULIN RECEPTOR SUBSTRATE I IN A PHOSPHOSERINE- DEPENDENT MANNER.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, 1 April 1997 (1997-04-01), US, pages 11663 - 11669., XP002915059, ISSN: 0021-9258 * |
KOSAKI A., ET AL.: "14-3-3BETA PROTEIN ASSOCIATES WITH INSULIN RECEPTOR SUBSTRATE 1 AND DECREASES INSULIN-STIMULATED PHOSPHATIDYLINOSITOL 3'-KINASE ACTIVITY IN 3T3L1 ADIPOCYTES.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, 1 January 1998 (1998-01-01), US, pages 940 - 944., XP002915060, ISSN: 0021-9258, DOI: 10.1074/jbc.273.2.940 * |
OGIHARA T., ET AL.: "14-3-3 PROTEIN BINDS TO INSULIN RECEPTOR SUBSTRATE-1, ONE OF THE BINDING SITES OF WHICH IS IN THE PHOSPHOTYROSINE BINDING DOMAIN.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, 1 October 1997 (1997-10-01), US, pages 25267 - 25274., XP002915058, ISSN: 0021-9258, DOI: 10.1074/jbc.272.40.25267 * |
See also references of EP1010433A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1010433A1 (en) | 2000-06-21 |
EP1010433A4 (en) | 2004-09-22 |
US6498139B1 (en) | 2002-12-24 |
US20020132759A1 (en) | 2002-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kagan et al. | 14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity | |
Weinman et al. | NHERF associations with sodium− hydrogen exchanger isoform 3 (NHE3) and ezrin are essential for cAMP-mediated phosphorylation and inhibition of NHE3 | |
Tunduguru et al. | Promoting glucose transporter-4 vesicle trafficking along cytoskeletal tracks: PAK-Ing them out | |
Mount et al. | Acute renal ischemia rapidly activates the energy sensor AMPK but does not increase phosphorylation of eNOS-Ser1177 | |
Morris et al. | Evidence for an insulin receptor substrate 1 independent insulin signaling pathway that mediates insulin-responsive glucose transporter (GLUT4) translocation. | |
EP2851084B1 (en) | Modulation of the Vps10p-domain receptors for the treatment of cardiovascular disease | |
US5726027A (en) | Method for treatment of insulin resistance | |
US20170318057A1 (en) | Modulation of the VPS10P-Domain Receptors for the Treatment of Cardiovascular Disease | |
US20120134985A1 (en) | Methods for modulating metabolic and circadian rhythms | |
JP2008537481A (ja) | Gタンパク質シグナリングを阻害する組成物及び方法 | |
WO1999016462A1 (fr) | Medicaments utilises pour des maladies occasionnees par une resistance insulinique | |
Frasca et al. | Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling | |
US20060094013A1 (en) | Salt-inducible kinases 2 and use thereof | |
PT1701978E (pt) | Utilização de caderina-t solúvel no tratamento de distúrbios metabólicos | |
JP5495249B2 (ja) | 新規化合物、リン酸化阻害剤、インスリン抵抗性改善剤、及び糖尿病の予防乃至治療剤、並びに、スクリーニング方法 | |
CA2405311A1 (en) | Multiprotein-complexes comprising a nmda receptor and uses thereof | |
Chandan et al. | Signaling, Physiology, and Targeting of GPCR‐Regulated Phospholipase C Enzymes | |
US20130065825A1 (en) | Compositions and Methods for Delaying Senescence or Cell Death in Neurons | |
US20130039857A1 (en) | Methods of suppressing cancer, increasing weight loss and/or increasing insulin sensitivity | |
US11306122B2 (en) | Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor | |
DEUTSCH | GEORGE GRUNBERGER, 1*, SURESH T. MATHEWS, 2 AND DIANE | |
WO2005065702A1 (ja) | GPR103-like受容体蛋白質に対するリガンドの新規用途 | |
Le | Investigation of molecular signaling defects in PTP alpha-deficient mice: insulin and NMDA receptor signaling | |
Marín-García et al. | Calcium Signaling: Receptors, Effectors, and Other Signaling Pathways | |
Dave | Molecular mechanisms of functional Gsα-tubulin interactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998944230 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09508691 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998944230 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998944230 Country of ref document: EP |